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SynapsesTo evaluate the potential importance in autistic subjects of copy number variants (CNVs) that alter genes of
relevance to bioenergetics, ionic metabolism, and synaptic function, we conducted a detailed microarray
analysis of 69 autism probands and 35 parents, compared to 89 CEU HapMap controls. This revealed that
the frequency CNVs of≥100 kb and CNVs of≥10 Kb were markedly increased in probands over parents
and in probands and parents over controls. Evaluation of CNVs≥1 Mb by chromosomal FISH conﬁrmed the
molecular identity of a subset of the CNVs, some of which were associated with chromosomal rearrange-
ments. In a number of the cases, CNVs were found to alter the copy number of genes that are important in
mitochondrial oxidative phosphorylation (OXPHOS), ion and especially calcium transport, and synaptic
structure. Hence, autism might result from alterations in multiple bioenergetic and metabolic genes required
for mental function. This article is part of a Special Issue entitled: 17th European Bioenergetics Conference
(EBEC 2012).
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The term autism is applied to a triad of symptoms including com-
munication deﬁcits, impaired social interactions, and repetitive ste-
reotypic behaviours [1]. Autism manifestations also occur in diseases
with deﬁned genetic etiology, e.g. Timothy syndrome, Angelman syn-
drome, Tuberous sclerosis, Fragile X mental retardation, Rett syn-
drome, etc. [2]. However, in the majority of cases the underlying
pathogenic mechanisms that lead to this symptom complex are not
deﬁned.
There is growing evidence that genomedosage changes can contrib-
ute to the etiology of autism. These can result from cytogenetically de-
tectable chromosomal changes to sub-microscopic changes detected
through microarray analyses and comparative genomic hybridization.
Among the earliest surveys of autism patients for sub-microscopicopean Bioenergetics Conference
EpigenomicMedicine, Children's
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l rights reserved.genomic alterations (deletions or duplications) it was reported that
copy number variants (CNVs) were found in 10% of sporadic autism pa-
tients, 3% of multiplex families, and 1% of controls [3,4].
While a speciﬁc nuclear DNA (nDNA) CNV may lead to autism in
some individuals it might manifest as cognitive impairment, attention
deﬁcit hyperactivity disorders, or psychiatric manifestations in others
[5]. This suggests that neuropsychiatric disorders might have a com-
mon pathophysiological basis and that variation in the clinical mani-
festations might reﬂect interactions between the gene dosage affects
caused by the CNV and other genetic, epigenetic, and/or environmen-
tal modifying factors.
It is still unclear if autism and other neuropsychiatric diseases are
caused by one of a few relatively rare large (greater than 1 megabase)
genome copy number dosage changes or whether smaller rare copy
number variations in speciﬁc combinations also play roles in autism
pathogenesis. Whatever the nature of the CNVs, it is clear that they
must alter the copy of one or more genes in which gene dosage
changes are sufﬁcient to cause disease. Deletion, duplication, or muta-
tions of such genes could then perturb cellular function sufﬁciently to
cause neuronal symptoms. Mutation of an active copy of an imprinted
gene could have such an effect or deletion of the normal copy of a
gene whose homologue was mutated. Alternatively, the expressivity
of one CNV might be inﬂuenced by the interaction with another
CNV [6].
Given that the CNVs that have been found associated with autism
are dispersed throughout the nDNA, then alteration of a copy of
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tism. This implies that the pathophysiology of autismmight be the re-
sult of perturbation of a genetic network all of whose gene functions
contribute to optimal neurological function. One such network could
be the roughly one to two thousand nDNA genes plus the thousands
of copies of the mitochondrial DNA (mtDNA) genes that are required
to assemble the mitochondrion and the mitochondrial energy gener-
ating pathway, OXPHOS. In addition to generating most of the cellular
energy, the mitochondrion regulates cellular oxidation–reduction
states, reactive oxygen species production, cytosolic and mitochon-
drial calcium levels, and apoptosis via activation of the mitochondrial
permeability transition pore (mtPTP). Since the brain has the highest
mitochondrial energy demand, then partial defects in mitochondrial
energy production or calcium homeostasis could be expected to pref-
erentially affect synaptic function and result in neuropsychiatric dis-
ease [2,7,8].
Alterations in mitochondrial structure and function have been re-
peatedly observed in autistic patients [1,9–15], and alterations in the
mtDNA have been reported in some cases of autism spectrum disorder
[16–18]. The activity of the mitochondrial inner membrane Calcium-
regulated aspartate/glutamate carrier (AGC) gene, SLC25A12, and/or
its expression have also been reported to be increased in autistic pa-
tients, at least in part due to elevated levels of calcium in the brains
of autism patients [19–21].
Therefore, we reasoned that CNV alteration in anyone of a wide
variety of bioenergetic, ion transport, of synaptic structural genes
might predispose to autism. To test this hypothesis, we surveyed
the CNVs in a set or carefully phenotyped autism patients and in a
number of cases their parents and then asked if the CNVs encom-
passed genes that would be important in mitochondrial function,
ion metabolism, and synaptic structure.
2. Methods
These studies were carried out at University of California Irvine
with Institutional Review Board approvals (1996-616 and 2002-
2608) and at the University of California San Diego with Institutional
Review Board approvals (090243 and 0807260) for human subject
research. Parents/guardians gave informed consent to participate in
the study for probands and for themselves and other children.
When appropriate, informed assent was obtained from probands.
Criteria used to establish autism diagnosis included ADOS (autism
diagnostic observation schedule), ADI (autism diagnostic inventory),
and in some cases CARS (Childhood Autism Rating Scale). Subjects
underwent testing of cognitive abilities using Mullen or Stanford
Binet tests depending on the proband age and abilities. Family history
was obtained and geneticists with expertise in dysmorphology and
neurologists examined probands. Clinical chemistry and metabolic
analyses, including organic and amino acid proﬁles were obtained.
In two autistic probands where blood chemistries indicated possible
mitochondrial functional impairment, muscle biopsy was obtained
for biochemical studies.
Blood was drawn from probands and parents and in some cases
from siblings and was used to establish lymphoblastoid cell lines.
DNA from the cells was used in microarray analyses.
The total number of autistic probands studied was 69, including 7
sets of monozygotic twins and 4 affected sib pairs. We also studied 35
parents. For control data we utilized data information on DNA of lym-
phoblastoid cell lines of Hap Map CEU individuals (control population
of northern and western European ancestry).
Microarray analyses were performed using the Affymetrix 6.0 SNP
arrays. The SNP (single nucleotide polymorphism) genotypes and
CNVs were determined using the Genotyping Console version 3.0.2
(Affymetrix Inc., 2008). Cell intensity ﬁles (CEL ﬁles) were created
which contain the images of the scanned probe set, including copy
number and allele-speciﬁc SNP probes. The software determines thenumber of copies present by comparing the signal intensity of the
probes and comparing them to the Hap Map reference data. The copy
number variants can then be visually appreciated using the Genotyping
Console. TwoQuality Control (QC)measures are used in theGenotyping
Console to insure the data is sufﬁcient for analysis. The ﬁrst QC step is
the Contrast QC measurement. The second QC measure is the Median
of the Absolute values of all Pairwise Differences (MAPD). The MAPD
measure analyzes the variability of log2 ratios of adjacent probes. All
samples used in the analyses presented here met QC standards on
both measures.
Data were analyzed using the Affymetrix genotyping console and
two sets of search parameters were used. In the ﬁrst set we searched
for CNVs that included 20 markers, and extended over segments that
were greater than 100 kb in length, with no more than 60% overlap
with known polymorphic variants designated in the Database for
Genomic variants (abbreviated as 20m100k60o). In a second search
we documented genomic changes detected by 20 markers within
segments larger than 10 kb and with no overlap with known copy
number variants (abbreviated as 20m10k0o). Microarray data used
in these analyses passed Affymetrix quality control measures, i.e.
MAPD b0.35 and contrast QC>1.7.
Cell lines from 14 of the 15 autistic probands who were found to
harbor CNVs larger than 1 megabase were examined by metaphase
chromosomes ﬂuorescence in situ hybridization (FISH).
Two of the patients, one with a few (2) CNVs and another with a
large number (13) of CNVs, were then analyzed for systemic mito-
chondrial OXPHOS dysfunction. A muscle biopsy was collected and
the electron transport chain enzymes assayed [22,23].
3. Results
3.1. Frequency of copy number variants detected in microarray analyses
If mutations in anyone of a number of genes involved in an inte-
grated pathway could cause autism, we hypothesized that individuals
with more CNVs would be more likely to manifest autism. To deter-
mine if autism probands harbor more CNVs than their parents or pop-
ulation controls, we used Affymetrix 6.0 microarray analysis to
identify CNVs in lymphoblastoid cell lines derived from the autism
probands and their parents and we compared these to those reported
in the lymphoblastoid cell lines derived from 89 CEU Hap Map sub-
jects that had been analyzed using the same microarray platform.
The number and frequency of variants detected using criteria
20m100k60o and criteria 20m10k0o are presented in Supplemental
Tables 1A and B, respectively, with gains and losses listed separately.
Because estimations of the overall frequency of CNVs may be inﬂu-
enced by cases with large numbers of variants, we graphed the fre-
quency of patients versus the numbers of CNVs per individual in
categories: 0 CNVs, 1 CNV, 2–5 CNVs, 6–10 CNVs, etc.
The numbers of CNVs per subject using search parameters
20m100k60o for probands, parents, and CEU controls show highly
signiﬁcant differences (pb0.00005) in CNV frequency between autis-
tic probands and CEU controls and between parents of autistic sub-
jects and CEU controls (Fig. 1, Supplemental Table 1a). Furthermore,
CEU control samples were more likely to have no large CNVs detected
and only 2% of the CEU control samples had more than one large CNV.
This compares to 36% of the proband samples and 25% of the parental
samples. The mean number of CNVs per subject in the category
20m100k60o is 1.6 for probands, 0.94 for parents, and 0.16 for CEU
controls.
Highly signiﬁcant differences in frequency of CNVs in autistic pro-
bands and their parents were also observed in the category of vari-
ants detected using the 20m10k0o criteria (p=0.0001). The mean
number of CNVs per subject in this category is 9.0 for proband, 2.5
for parents of autistic probands, and 0.14 for CEU controls (Fig. 2,
Supplemental Table 2).
Fig. 1. The relative frequency of CNVs in probands, parents, and CEU controls by stan-
dard criteria. Criteria for inclusion in this analysis are CNVs that encompass≥20 SNP
markers, are≥100 kilobases in length, and cannot overlap more than 60% with a pre-
viously identiﬁed variant (20m100k60o). The frequency of CNVs is much greater in
the patients than in parents, and CNV frequency is greater in patients and parents
than in controls (Kruskal–Wallis non-parametric test, pb0.00005).
Fig. 3. FISH Analysis of 2p:12p translocation resulting in the deletion of CACNA1C and
CACNA2D4. Green = chromosome 2p probe which marks the translocated region and
hence results in three copies, Red = chromosome 12q probe which marks the bottom
of chromosome 12, this region is not rearranged. Translocation of the tip of the short
arm of chromosome 2 (2p) onto the tip of the short arm of chromosome 12 (12p), re-
places a section of the short arm of chromosome 12p with the transferred end of the
short arm of chromosome 2p. Loss of one of the two chromosomal copies of 12p
removes 27 genes including CACNA1C and CACNA2D4. Generation of an extra copy
of the 2p duplicates 12 genes including SNTG2.
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samples were available from both parents and their autistic child.
Using the search criteria 20m10k0o we determined that 16 of the
145 CNVs (11%) observed in probands were inherited from a parent.
3.2. Genes involved in megabase sized multigenic CNVs
If CNVs associated with autism generate the phenotype because
they alter the genes of an integrated bioenergetic, ion metabolism,
and synaptic structural gene network, then we hypothesized that au-
tismassociated CNVs should encompasses one ofmore genes important
for these functions. Accordingly, we performed a detailed analysis of
CNVs larger than 1 megabase (mb) in 15 autistic probands. In 14 of
these cases we also analyzed the metaphases using FISH in an attempt
to verify the molecular defect.
In one sib pair affected with autism and developmental delay we
identiﬁed an approximately 4-megabase deletion on chromosome
12p and a similar sized duplication on chromosome 2p. Previously,
these siblings had been reported as having normal karyotypes on
the basis of clinical cytogenetic studies. By FISH analysis we found
that the siblings carried a 2p:12p translocation. This translocation
led to replacement of the terminal region of chromosome 12 (12p)
with material from 2p (Fig. 3). This translocation resulted in the dele-
tion from one homologue of chromosome 12 of 27 genes includingFig. 2. The relative frequency of CNVs in probands, parents, and CEU controls by the
most exacting criteria. Criteria for inclusion in this analysis are CNVs that encom-
pass≥20 SNP markers, are≥10 kilobases in length, but do not overlap at all with any
previously identiﬁed variant (20m100k0o). The frequency of CNVs is much greater in
the patients than in parents, and CNV frequency is greater in patients and parents
than in controls (Kruskal–Wallis non-parametric test, pb0.00005).the calcium ion channel genes CACNA1C and CACNA2D4. The duplica-
tion of 2p25 material led to increased copy number of 12 genes, in-
cluding SNTG2 (Table 1, AU55-202 & AU55-204). These siblings
showed marked growth retardation with height at the 10th percen-
tile and weight at the 5th percentile.
The chromosome regions involved in the 1 megabase CNV and the
numbers of genes encompassed are listed in Table 1. In Table 2 weTable 1
CNV larger than 1 megabase in autistic probands detected by Affymetrix 6.0 SNP arrays
and FISH.
Case ID Chrom. region. Prox. bp Distal bp Change Genes
AU28-202 15q24.1–q24.2 70,750 kb 73,860 kb Deletion 37
AU52-201 4q32.1–q34.2 157,975 kb 176,835 kb Deletion 32
AU09-202 15q11–q13.3 18,200 kb 30,700 kb Duplication 29
AU64-201 15q11–q13.3 18,200 kb 32,000 kb Duplication 29
29-AH 15q13.2–q13.3 28,700 kb 30,320 kb Deletion 7
AU210202 15q11.2–q13.1 21,192 k 26,500 k Duplication 12
AU24-201 15pter–q11 1 k 8000 kb Extra chrom. 3
AU78-202 2q37.2–q37.3 235,663 kb 243697 kb Deletion 31
AU50-201 13q13.3–q14.11 33,949 kb 43,438 kb Deletion 39
69 AF Xp11.23–p11.22 47,961 kb 52,723 kb Duplication 66
AU55-202 2pter–p25.2 2 kb 4981 kb Duplication 12
AU55-204 2pter–p25.2 2 kb 4981 kb Duplication 12
AU55-202 12pter–p13.2 6 kb 4.006 kb Deletion 25
AU55-204 12pter–p13.2 6 kb 4.006 kb Deletion 25
AU69-201 7p22.2–p21.3 10.338 kb 11.732 kb Deletion 3
AU69-202 7p22.2–p21.3 10.338 kb 11.732 kb Deletion 3
AU69-202 2pter–2cent. 1 kb 80 MB Duplication Many
AU69-202 7pter–7p22.3 160 kb 4400 kb Deletion 9
AU81-201 1q21.1 144,570 kb 147,300 kb Duplication 11
Table 2
Mitochondrial functions.
A. Genes affected by CNVs≥1 Mb studied by microarrays and FISH
Proband ID Chromosome region Position and extent in Kb Number of genes Genes of interest
28-202 15q24.1–15q24.2 73,420–75,932 del. 45 PPCDCa, COX5Aa, SIN3A, SEMA7A, CYP11A1a,
CYP1A1, CYP1A2
64-201 15q11–15q13.3 2000–32,940 dup. >80 NDN, SNURPN, SNORD-HBI, UBE3A,
ATP10A, GABRA5b, GABRB3b,
GABRG3b HERC2, OCA2, APBA2,
CHRNA7b, SCG5
09-201 15q11–15q13.3 2000–32,940 dup. >80 NDN, SNURPN, SNORD-HBI, UBE3A,
ATP10A, GABRA5b, GABRB3b,
GABRG3b, HERC2, OCA2, APBA2, SCG5
210-202 15q11.2–15q13.1 21,200–28,700 dup. >80 NDN, SNURPN, SNORD-HBI, UBE3A,
ATP10A, GABRA5b, GABRB3b,
GABRG3b, HERC2
AH 15q13.3 30,670–32,460 del. 14 ARHGAP11B, TRPM1, KFL13,
CHRNA7b
069AF Xp11.23–p11.21 47,961–52,723 dup 14 CLCN5, AKAP4, DGKKc, SHROOM4
50-201 13q13.2–13q14.11 35,400–43,903 del 44 NBEA, SLC25A15a, MTRF1c, DGKH,
ENOX1, AKAP11
52-201 4q32.1–4q32.2 157,977–176,836 del 61 ETFDHa, CBR4a CLCN3, GLRBb
GPM6b
78-202 2q37.2–q37.3 236,307–243,819 del 78 NDUFA10a, D2HGDHa,
CENTG2, HDACA4, UBE2F, AGXT
B. CNVs detected ﬁrst by microarrays and then conﬁrmed by FISH
Proband ID Chromosome region Extent in KB Number of genes Genes of interest
55-202, 55-204 2pter–p25.3 dup 0–4498 dup. 12 SNTG2, PXDN, TPOc
55-02, 55-204 12pter– p25.2 0–3930 del. 27 CACNA1Cb, CACNA2D4b SLC6A12, SLC6A13,
RAD52, ERC1, FKBP4
CNV in both members of monozygotic twin pair microarray only
69-201, 69-202 7p21.3 10,340 K–11,720 K 2 NDUFA4a, PHF4
Mitochondrial Functions
15q24.1–15q24.2.
PPCDC: Phosphopantothenoylcysteine decarboxylase involved in the biosynthesis Coenzyme A.
COX5: Cytochrome c oxidase subunit Va, a subunit of OXPHOS complex IV.
CYP11A: Mitochondrial inner membrane enzyme that catalyzes the conversion of cholesterol to pregnenolone.
13q13.2-14.11
SLC25A15: Member of the mitochondrial carrier family, transports ornithine across the inner mitochondrial membrane from the cytosol to the mitochondrial matrix.
MTRF1: Mitochondrial protein with similarity to the peptide chain release factors (RFs).
4q32.1–q32.2
ETFDH: Electron-transferring-ﬂavoprotein dehydrogenase reduces ubiquinone in the mitochondrial membrane using electrons derived from fatty acid oxidation within the matrix
borne by the mitochondrial electron-transfer ﬂavoprotein.
CBR4: Carbonyl reductase 4 mitochondrial location NAD(P)H dehydrogenase quinone activity.
2q37.2–q37.3
NDUFA10: A component of the NADH dehydrogenase (ubiquinone) oxidoreductase (OXPHOS complex I).
D2HGDH: D-2hydroxyglutarate dehydrogenase, a mitochondrial enzyme belonging to the FAD-binding oxidoreductase/transferase type 4 family.
7p21.3
NDUFA4: A component of the NADH dehydrogenase (ubiquinone) oxidoreductase (OXPHOS complex I).
Ion channel functions
15q11–q13.3
ATP10A: A member of the family of P-type cation transport ATPases.
CHRNA7: A subunit of the nicotinic acetylcholine receptors (nAChRs), members of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses.
GABRA5, GABRB3, GABRG3: Distinct subunits of a multisubunit chloride channels that serves as the receptors for gamma-aminobutyric acid.
TRPM1: A calcium permeable cation channel4q32.1–q32.2.
CLCN3: A member of the voltage-gated chloride intracellular channel family.
GPM6: A neuronal membrane glycoprotein with calcium channel activity.
12pter-p25.2
CACNA1C: An alpha-1 subunit of a voltage-dependent calcium channel.
CACNA2D4: a member of the alpha-2/delta subunit family, a protein in the voltage-dependent calcium channel complex.
a Mitochondrial location or function.
b Ion channel related.
c Metabolic function.
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CNVs and note genes involved in mitochondrial functions and ion
metabolism.
Multi-gene duplications of 15q11.1–15q11.3 were found in three
cases and included the SNRPN and UBE3A genes (see Table 1). In
two cases the duplications also involved the GABA receptor genes
GABRB3, GABRA5 and GABRG3. Our studies on parents in these cases
revealed that the abnormalities arose de novo in the affected children.
Studies of polymorphic markers revealed that the largest duplications(cases AU09-202 and AU64-201) arose on maternal chromosomes,
the duplication in case AU210-202 arose on a paternal chromosome.
Analysis of autistic manifestations and degree of cognitive impair-
ment in the three cases with 15q duplications revealed that the phe-
notype was much milder in AU210-202, where the interstitial
duplication of 15q11.2–q13.1 arose on a paternal chromosome.
Our microarray studies conﬁrmed the presence of a 15q13.3 dele-
tion in a case of autism that had prior clinical cytogenetic studies. We
also studied the parents of this proband and determined that the
Table 3
Relative skeletal muscle mitochondrial electron transport chain activities in autistic
probands with low and high CNV level.
Case CNV # CS CI CI/CS CII+CIII CII+CIII/CS CIV CIV/CS
1 2 0.93 89.4 96.1 155 167 0.68 0.73
2 13 1.75 62.8 36.0 571 327 1.06 0.61
X(SD) 1.31(0.46) 81(29.4) 263(196) 0.69(0.32)
Range 0.67-2.3 50-134 88-659 0.27-1.2
CS= citrate synthase (µmol/min/mg protein), CI= complex I (NADH-CoQ1 oxidoreductase,
nmol/min/mg protein), CII+CIII = complex II + complex III (succinate-cytochrome c
oxidoreductase, nmol/min/mg protein), CIV = complex IV (cytochrome c oxidase, rate
constant/mg protein). X(SD) = mean and standard deviation, Range = extent of normal
values.
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chemical evaluation revealed slight increases in long chain organic
acids and increased acylcarnitine during one hospitalization for eval-
uation of a seizure disorder. On carnitine supplementation organic
acid levels were normal and free carnitine and acylcarnitine blood
levels were in the normal range.
We carried out microarray studies to more accurately deﬁne chro-
mosome deletion breakpoints and impacted genes in four patients
with autism where cytogenetic and clinical data where previously
reported. Deletions in these patients involved 15q24.1 (AU28-202),
4q32.1-q34.2 (AU52-201), 2q37.2-q37.3 (AU78-202) and 13q13.3–
q14.11 (AU50-201). In autism case AU28-202, a 15q deletion, was
found to remove the promyelocytic leukemic (PML) locus and sur-
rounding genes [24]. This region also encompassed other important
mitochondria genes (see Table 2). Deletion of 15q24.1–15q24.2 re-
moved the mitochondrial genes COX5A and PPCDC. COX5A is a subunit
of complex IV and PPCDC encodes phosphopantothenoyl-cysteine de-
carboxylase which is involved in the generation of the acyl carrier
molecule, coenzyme A. Coenzyme A, in turn, is involved in the syn-
thesis of Coenzyme Q, and both are central to mitochondrial function.
Consistent with these associations, physiological studies of this pa-
tient revealed elevated alanine levels which are commonly seen in
patients with mitochondrial dysfunction.
Female monozygotic twins, AU69-201 and AU69-202, who met
ADOS criteria for autism and with developmental delay, were evalu-
ated at age 10 years. These twins were both found to harbor a dupli-
cation on chromosome 7p that was 1.4 mb in size. We further
mapped the duplication to 7p21.3–p22.2, extending from 10,338 K
to 11,732 K. This region encompassed the NDUFA4 gene that encodes
a subunit of mitochondrial OXPHOS complex I as well as PHF4 in-
volved in epigenetic chromatin regulation and THSD7A that encodes
a subunit of thrombospondin.
Two cases were examined for mitochondrial OXPHOS defects in
skeletal muscle mitochondria, case 1 with two CNVs (a low number)
and case 2 with 13 CNVs (a high number) (Table 3). Case 1 shows
normal electron transport chain enzyme levels. By contrast, case 2
shows a clinically signiﬁcant complex I defect, the patient's complex
I activity being 44% of the mean normal value and 28% below the low-
est normal value. Therefore, this data raises the possibility that the se-
verity of an autism patient’s mitochondrial defect may be related to
the number of genetic alterations that impact nuclear genes related
to energy metabolism.3.3. Discussion and signiﬁcance
Our study has demonstrated that there is a direct correlation be-
tween the autism phenotype and the number of CNVs, with the num-
ber of CNVs in the parents of autistic children being intermediate
between the probands and the controls. Hence, an increase in the
number of CNVs increases the probability of developing autism.Analysis of the genes encompassed by well deﬁned CNVs con-
ﬁrmed that CNVs frequently altered genes involved in mitochondrial,
ion channel, and synaptic function. Since both mitochondrial function
and ion transport are important for synaptic function, alterations in
any of these genes could affect synaptic function and create a neuro-
psychiatric phenotype [2].
While some rearrangements were seen more than once, others
were seen only once in our sample. The most common CNV occurred
at 15q11–q13.3. This region encompasses the UBE3A gene, deﬁciency
of whichwe have shown in amousemutant speciﬁcally alters the hip-
pocampal mitochondrial morphology and brain complex II/III speciﬁc
activity [25]. Other CNVs altered the copy number of genes known to
be important in mitochondrial function including NDUFA4, NDUFA10,
PPCDC, COX5, CYP11A, SLC25A15, MTRF, ETFDH, and CBR4 (Table 2).
There is now evidence that recurrent 15q24 microdeletion events
occur in individuals in various populations and that this microdele-
tion is associated with intellectual disability, speech problems, and
frequently with autism. A study of 15 cases with 15q24.1–15q24.2 de-
letions also led to the conclusion that several genes in this region like-
ly played roles in determining intellectual disability [26]. Since this
region encompasses the COX5A and PPCDC genes, this recurrent
microdeletion is consistent with our hypothesis that a subset of au-
tism CNVs do seem to coincide with important nuclear encoded mito-
chondrial gene loci [27].
Other CNVs were found to alter ion transport genes. A 2p:12p
chromosomal translocation was found in two autistic siblings. It
leads to deletion of 12p that removes one copy each of the CACNA1C
and CACNA2D4 calcium channel genes. Mutations in the CACNA1C
gene, generally at codon G406R, cause Timothy syndrome [28]. The
CACNA1C protein is a T-type voltage-gated Cav1.2 channel and its
mutation in Timothy syndrome results in Long QT syndrome and au-
tism. Cav1.2 shows its highest expression in the hippocampus, amyg-
dala, and putamen [29]. The CACNA2D4 gene has a more limited range
of tissue expression than CACNA1C, being expressed primarily in eye
and retina, in the pituitary, and adrenal gland.
An independent study reported ﬁndings on two children who
manifested developmental delay and impaired social interactions.
They were found to have an interstitial deletion on 12p13.33 that im-
pacted eight genes including CACNA1C, CACNA2D4 and ERC1 [30]. A
survey of the CACNA1H gene, a close paralog of the Timothy syndrome
Ca++ channel, in 461 autism DNAs revealed six newmutations. Func-
tional studies of two of these mutant proteins, R212C and R902W,
revealed extended Ca++ inﬂux into the cytosol [31]. There is growing
evidence for the importance of CACNA1C in brain function and evi-
dence that speciﬁc allelic variants and genotypes of CACNA1C occur
with higher frequency in patients with mental illness including bipo-
lar disease, recurrent major depression and schizophrenia [32,33].
Also CACNA1C genotype can inﬂuence verbal ﬂuency in healthy indi-
viduals [34].
Calcium levels have been found to be elevated in the brains of au-
tism patients and this appears to activate the mitochondrial AGC
which is central to the cytosol–mitochondrial NADH shuttle system
[19]. Cytosolic calcium levels are regulated by mitochondrial calcium
uptake, driven by the mitochondrial inner membrane potential (ΔP).
This involves the mitochondrial Ca++ uniporter [35,36] which inter-
faces with the type 3 inositol triphosphate receptor (IP3R) receptors
in the endoplasmic reticulum (ER) located in the mitochondrial asso-
ciated membranes (MAMs). The promyelocytic leukemia (PML) pro-
tein whose gene at 15q is deleted in AU28-202 is associated with
this complex [37]. Excessivemitochondrial uptake of calcium can acti-
vate the mitochondrial permeability transition pore (mtPTP) causing
cell death [38]. Other CNVs also encompassed transport genes includ-
ing GPM6, TRPM1, (GABRA5, GABRB3, GABRG3), CLCN3, CHRNA7 and
ATP10A (Table 2).
One patient report links mitochondrial dysfunction with ion chan-
nel disruption. This patient carried a de novo translocation between
1801M. Smith et al. / Biochimica et Biophysica Acta 1817 (2012) 1796–1802chromosomes 1 and 15, t (1; 15) (p36.11: q24.2) which interrupted
the CLIC4 intracellular chloride channel 4 gene on 1p36.11 and the
PPCDC gene on 15q24 which was split between exons 1 and 3. In ad-
dition, the translocation decreased the expression of the SCAMP5 gene
close to the 15 translocation breakpoint [39].
Other CNVs appear to impact synaptic structure and function. The
duplication of 2p25 material added an additional copy of the SNTG2
gene (Fig. 3). Previously, we reported that patient 50‐201 with a
13q deletion was hemizygous for a number of genes including the
very large neurobeachin (NBEA) gene [40]. Disruption of the NBEA
gene has been reported in another autism patient [41] and knockout
of NBEA in mice led to a reduced number of dendritic spine synapses
in cultured neuronal cells [42].
4. Conclusion
Our study conﬁrmed the correlation between increased numbers
of CNVs and risk of developing autism and revealed that some pa-
tients with CNVs can also manifest mitochondrial dysfunction. By
carefully mapping the CNVs we have observed that CNVs in autistic
patients commonly encompass genes important in mitochondrial
function, ion transport, and synaptic structure and function. Since
the nucleus contains between one and two thousand mitochondrial
genes plus numerous ion transport genes, it is conceivable that the re-
moval of any one of a large number of different genes necessary to
maintain this integrated bioenergetic, signaling, and synaptic struc-
tural gene network could adversely affect synaptic function and
thus result in autism. If this speculation is correct, it might explain
why it has been so difﬁcult to identify individual structural genes
that cause neuropsychiatric disorders.
Supplementary data related to this article can be found online at
http://dx.doi.org/10.1016/j.bbabio.2012.04.004.
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